{"id":58834,"date":"2026-03-14T00:43:54","date_gmt":"2026-03-13T23:43:54","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/03\/14\/il-1r2-deficiency-unleashes-neutrophil-mediated-antitumor-potential-in-sarcoma\/"},"modified":"2026-03-14T00:43:54","modified_gmt":"2026-03-13T23:43:54","slug":"il-1r2-deficiency-unleashes-neutrophil-mediated-antitumor-potential-in-sarcoma","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/03\/14\/il-1r2-deficiency-unleashes-neutrophil-mediated-antitumor-potential-in-sarcoma\/","title":{"rendered":"IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Mar 13. doi: 10.1158\/2326-6066.CIR-25-0651. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Interleukin-1 (IL-1) plays dual functions in cancer. It promotes cancer-related inflammation and progression, but also influences leukocyte functional activation. IL-1 receptor 2 (IL-1R2) functions as an IL-1 decoy receptor, inhibiting IL-1 activity. Here, we investigated the contribution of IL-1R2 in tuning IL-1-dependent effects in mouse models of cancer, including colorectal cancer, lung cancer, and primary and metastatic transplantable and chemically induced sarcoma. Even though the prominent role of IL-1 is pro-tumoral, IL-1R2 deficiency was selectively associated with reduced sarcoma growth, whereas it was irrelevant in other pre-clinical models investigated. IL-1R2 deficiency was associated with a massive infiltration of neutrophils in the tumor, neutrophilia, and increased extramedullary emergency granulopoiesis. Neutrophils were crucial for tumor control in IL-1R2-deficient mice. Immunophenotypic and transcriptional profiling of sarcoma-infiltrating neutrophils revealed that IL-1R2 deficiency was associated with higher expression of activation or maturation markers, and with gene expression reprogramming, with downregulation of pathways associated with pro-tumoral functions. In sarcoma patients, the IL-1R2 deficiency gene signature correlated with better clinical outcomes. Thus, this study shows that IL-1R2 tunes IL-1-driven cancer-associated emergency granulopoiesis and neutrophil functional activation to an antitumor mode in sarcomas and reveals the antitumor potential of neutrophils in this tumor.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41824510\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260313194342&amp;v=2.19.0.post6+133c1fe\">41824510<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0651\">10.1158\/2326-6066.CIR-25-0651<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Mar 13. doi: 10.1158\/2326-6066.CIR-25-0651. Online ahead of print. ABSTRACT Interleukin-1 (IL-1) plays dual functions in cancer. It promotes cancer-related inflammation and progression, but also influences leukocyte functional activation. IL-1 receptor 2 (IL-1R2) functions as an IL-1 decoy receptor, inhibiting IL-1 activity. Here, we investigated the contribution of IL-1R2 in tuning IL-1-dependent &#8230; <a title=\"IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/03\/14\/il-1r2-deficiency-unleashes-neutrophil-mediated-antitumor-potential-in-sarcoma\/\" aria-label=\"Read more about IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-58834","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/58834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=58834"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/58834\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=58834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=58834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=58834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}